Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising cocktail targets tough lung cancer

NCT ID NCT05142696

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study tests a radioactive drug called Lutathera added to standard chemotherapy and immunotherapy for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to find a safe dose and see if the combination helps people live longer. About 24 participants will receive the treatment, and researchers will monitor side effects and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Lutathera (lutetium Lu 177 dotatate) plus carboplatin, etoposide, and atezolizumab
What this could lead to
If successful, this could offer a new treatment option that improves survival for people with an aggressive type of lung cancer.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply to everyone. The combination may cause serious side effects or not work better than current therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • AdventHealth

    Orlando, Florida, 32804, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Georgetown University Lombardi Cancer Center

    Washington D.C., District of Columbia, 20007-2197, United States

  • Hackensack University Medical Ctr

    Hackensack, New Jersey, 07601, United States

  • Novartis Investigative Site

    Linz, Upper Austria, 4020, Austria

  • Novartis Investigative Site

    Vienna, 1090, Austria

  • Novartis Investigative Site

    Montreal, Quebec, H2X 1R9, Canada

  • Novartis Investigative Site

    Beijing, 100036, China

  • Novartis Investigative Site

    Shanghai, 200032, China

  • Novartis Investigative Site

    Olomouc, 779 00, Czechia

  • Novartis Investigative Site

    Lille, 59000, France

  • Novartis Investigative Site

    Marseille, 13885, France

  • Novartis Investigative Site

    Montpellier, 34298, France

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Beersheba, 8457108, Israel

  • Novartis Investigative Site

    Ramat Gan, 5265601, Israel

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Singapore, 119228, Singapore

  • Novartis Investigative Site

    Singapore, 168583, Singapore

  • Novartis Investigative Site

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    Madrid, 28009, Spain

  • Novartis Investigative Site

    Madrid, 28040, Spain

  • Novartis Investigative Site

    Málaga, 29010, Spain

  • Novartis Investigative Site

    Guildford, Surrey, GU2 7XX, United Kingdom

  • St Louis University

    St Louis, Missouri, 63104, United States

  • University Cancer and Blood Center LLC

    Athens, Georgia, 30607, United States

  • University Hospitals Of Cleveland

    Cleveland, Ohio, 44106, United States

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.